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Abstract Dietary restrictions, including fasting (or long-term
starvation), calorie restriction (CR), and short-term starvation
(STS), are considered a strong rationale that may protect against
various diseases, including age-related diseases and cancer.
Among dietary approaches, STS, in which food is not con-
sumed during designed fasting periods but is typically not re-
stricted during designated feeding periods, seems to be more
suitable, because other dietary regimens involving prolonged
fasting periods could worsen the health conditions of cancer
patients, being they already naturally prone to weight loss.
Until now, the limited amount of available data does not point
to a single gene, pathway, or molecular mechanism underlying
the benefits to the different dietary approaches. It is well known
that the healthy effect is mediated in part by the reduction of
nutrient-related pathways. The calorie restriction and starvation
(long- and short-term) also suppress the inflammatory response
reducing the expression, for example, of IL-10 and TNF-α,
mitigating pro-inflammatory gene expression and increasing
anti-inflammatory gene expression. The dietary restriction
may regulate both genes involved in cellular proliferation and
factors associated to apoptosis in normal and cancer cells.
Finally, dietary restriction is an important tool that may influ-
ence the response to chemotherapy in preclinical models.
However, further data are needed to correlate dietary ap-
proaches with chemotherapeutic treatments in human models.
The aim of this review is to discuss the effects of various dietary
approaches on the cancer progression and therapy response,
mainly in preclinical models, describing some signaling path-
ways involved in these processes.
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Introduction
BLet food be thy medicine and medicine be thy food.^ This
sentence of Hippocrates explains excellently the importance
that feeding assumes in the establishment of a healthy life. In
particular, various dietary approaches, such as calorie restric-
tion and long- and short-term starvations, seem to be involved
in the protection from aging and age-related diseases.
Fasting (or long-term starvation) is commonly defined as a
prolonged deprivation of nutrients from a system that can be
represented by cells in culture (normal or immortalized) or by
multicellular organisms (from fruit flies to humans). In vitro
serum deprivation, for example, is often considered as a rou-
tine procedure to reduce basal cellular activity [1] and to make
the population homogeneous of proliferating cells that, in this
condition, can enter in the quiescent G0/G1 phase [2]. Its utility
includes the metabolic research in which the establishment of
serum starvation-based protocols submits the physiological
response to a hormonal change [3]. Moreover, other re-
searchers have used serum starvation as a system to analyze
molecular mechanisms involved in cellular stress response
[4], apoptosis, and autophagy [5, 6]. That is why serum star-
vation has also been referred to as Benvironmental stress^ [7]
and Bapoptotic trigger^ [8]. Recently, starvation is assuming a
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part of protagonist. In particular, it has been spreading the idea
that fasting cycles can prevent the onset of age-related dis-
eases [9] and to improve the response to certain therapies like
the oncological ones [10].
Like fasting, the reduction in calorie intake or calorie restric-
tion (CR), without malnutrition, has been indicated as a strong
non-genetic intervention that, simultaneously, can protect
against various diseases, like diabetes and cancer, and that can
increase the life-span in mammalians [11]. CR can consist of
feeding once daily or thrice weekly over a range of restricted
food amounts [12]. Also, it seems to cause a large number of
benefits by reducing cardiovascular risk factors [13], improving
insulin sensitivity [14], enhancing mitochondrial function (also
inducing the generation of new mitochondria) [15], increasing
cellular quality control through autophagy [16, 17], and reduc-
ing oxidative damage in both DNA and RNA [18].
The above considerations demonstrate that fasting or CR
could be applied to protect patients from toxic side effects of
chemotherapy. However, in vivo preclinical studies showed
that several months may be necessary for people under CR to
reach a protected state and, accordingly, these two types of
approaches are not feasible for patients already prone to
weight loss because of cancer itself or chemotherapy [19].
In this regard, another dietary approach that could generate
similar biological changes, such as fasting and calorie restric-
tion, seems to be more suitable. Short-term starvation (STS or
intermittent fasting) is considered as a limited exposure to
several nutrients, in which food is not consumed during de-
signed fasting periods but is typically not restricted during
designated feeding periods [11]. Other authors indicated it as
the period of time in which animals lose weight after initiation
of food restriction but prior to rebound or weight maintenance
[20]. Accumulating evidence suggests that STS can produce,
like CR, similar beneficial biological effects, including mod-
ulation of reactive oxygen species (ROS) and inflammatory
cytokines, and also antimutagenic, antibacterial, and anticar-
cinogenic effects [21, 22]. Moreover, it has been shown that
STS may be advantageous even after certain injuries. For ex-
ample, in rats, a day of fasting can promote recovery following
moderate but not severe damage in a controlled cortical im-
pact injury model [23].
This manuscript proposes to review literature data for a
better understanding of the correlation between the effects of
the dietary restriction and response to anticancer treatment.
Dietary restriction-induced molecular changes
Until now, the restricted available data do not point to a
single gene, pathway, or molecular mechanism underly-
ing the benefits of the different dietary approaches. It is
well known that the salutary effect is mediated in part
by the negative regulation of nutrient-signaling
pathways, including, in part icular, the growth-
promoting insulin-like growth factor 1 (IGF-1) receptor
and its downstream effectors, such as extracellular
signal-regulated kinase (ERK), c-Jun N-terminal kinase
(JNK), p38 mitogen-activated protein kinase (MAPK),
and phosphoinositide 3-kinase (PI3K), which are known
to regulate several detoxification enzymes [24] (Fig. 1).
The IGF-1 pathway influences both animal life-span and
oxidative stress sensitivity. IGF-1 receptor-deficient mice
showed a great resistance to oxidative stress [25]. The
Forkhead box protein O1 (FOXO1), a downstream target of
IGF-1/AKT signaling, is able to enter the nucleus, in the ab-
sence or reduction of IGF-1/AKT signaling, and to modulate
genes involved in oxidative stress resistance, metabolism, and
longevity [26–28].
Circulating IGF-1, in collaborations with other hormones
and growth factors, plays an important function in the regula-
tion of cell differentiation and proliferation and body size and
also exerts a tumorigenic effect on a variety of tumors by
promoting proliferation and inhibiting apoptosis [29, 30].
Consistent with the effect of calorie restriction and starva-
tion (short- and long-term) in reducing growth factor signal-
ing, fibroblasts isolated from mice deficient in the GH/IGF-1
pathway are resistant to oxidative stress, UV, heat, and
genotoxins [31]. On the other hand, exposure of murine hepa-
tocytes to IGF-1 reduces the levels of superoxide dismutases
and catalase activity [32].
Moreover, it has been shown that a fasting period of 24 h
does not alter the hepatic expression of many ABC family
members but induces the expression of Abca1 (involved in
cholesterol transport) and Abcg8 (involved in sterol transport)
[33].
Dietary restrictions (DRs) also suppress the inflammatory
response. Restricted rats have exhibited reduced mRNA ex-
pression levels of inflammatory cytokines and chemokines
(IL-1β, TNF-α, and MCP-1) in various tissues such as the
liver, kidney, and spleen [34]. Coherently, 4 weeks of DR
decrease signs of illness (fever, cachexia, etc.), mitigating
pro-inflammatory gene expression (for example, COX-2 and
leptin) and increasing anti-inflammatory gene expression
(e.g., SOCS3 and IL-10) [20].
Some researchers have submitted to serum starvation
primary human myotubes, rat L6 myotubes, and human
embryonic kidney cells for 24 h and assessed phosphor-
ylation changes in the energy-sensing AMP-activated
protein kinase (AMPK) and its downstream targets, in-
cluding acetyl-CoA carboxylase (ACC), ERK1/2, and
mammalian target of rapamycin (mTOR) pathway.
Additionally, the phosphorylation of AMPK, ACC, and
ERK1/2 reacted to serum starvation dynamically in a
time-dependent way. Changes induced in the mTOR
pathway after serum starvation can be associated with
growth factor deprivation [3].
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Different dietary approaches may regulate genes in-
volved in cellular proliferation, such as the insulin sig-
naling adaptor (Irs2) and mitogenic hormone prolactin
receptor (Prlr), in both normal and cancer cells [19]. It
has been demonstrated that the PI3K pathway is impor-
tant in determining the sensitivity of tumors to dietary
restrictions. In particular, mutations that make PI3K
constitutively active affect the response of cancer cells
to dietary restrictions [35]. Instead, studies showed that
STS had a greater effect in reducing glucose compared
to calorie restriction diets, even when the CR caused an
equivalent weight loss. This can be explained by the
fact that STS and calorie restriction diets have distinct
physiological responses. For example, short-term fasting
induced a 70 % decrease in blood glucose that occurred
within 60 h, while a 90 % CR diets caused only a
40 % glucose reduction after 96 h [21, 36].
Previous findings have clarified that serum starvation acti-
vates in cancer cells the ATM/Chk2/p53 pathway that sensi-
tizes them to chemotherapy with cisplatin, probably due to a
temporary loss of the coordination between cell proliferation
driven by oncogenic mutations and the growth stimulated by
growth factors [37].
Dong et al. [38] demonstrated, through in vitro studies
using A549 non-small cell lung cancer cell lines, that serum
starvation increases E-cadherin expression. E-cadherin is in-
volved in the pathobiology of several types of cancer: the loss
or dysfunction of E-cadherin is associated with increased lung
cancer cell proliferation and invasiveness [39].
Braun et al. [40] observed that starvation induces the in-
crease of p21 levels in MCF7 cell lines independently from
p53 and this mitigates the efficacy of the Puma/Bax-
dependent apoptotic signal (also induced by starvation). In
addition, the anti-apoptotic function exerted by p21 in starved
cells occurs upstream of mitochondrial permeabilization at the
level of the Puma interactions with Bcl-x. Therefore, p21 pro-
tects cells against starvation-induced apoptosis. Furthermore,
an important step for cellular apoptosis is the phosphorylation
of H2AX (a variant of the histone H2A family) that is medi-
ated byMAPK family proteins, such as JNK and p38. Several
data showed that serum starvation induces strongly the phos-
phorylation of p38 and H2AX at Ser139 in a time-dependent
Cell protection
Fig. 1 Insulin-like growth factor-1 (IGF-1) signaling pathway. IGF-1
insulin-like growth factor-1; IGF-1R insulin-like growth factor-1
receptor; SHC Src homology 2 domain-containing adaptor protein B;
SOS Son of Sevenless; GRB2 growth factor receptor-binding protein 2;
RAS rat sarcoma viral oncogene homolog; RAF RAF-1 proto-oncogene,
serine/threonine kinase; MEK1/2 mitogen-activated protein kinases 1/2;
ERK1/2 extracellular signal-regulated protein kinases 1/2; IRS1 insulin
receptor substrate 1; IRS2 insulin receptor substrate 2; p85
phosphatidylinositol 3-kinase 85-kDa regulatory subunit alpha; P110
PI3K phosphatidylinositol 3-kinase, catalytic, 110-kDa, alpha; PIP2
phosphatidylinositol 4,5-bisphosphate; PIP3 phosphatidylinositol 3,4,5-
trisphosphate; PTEN phosphatase and tensin homolog; PDK1 pyruvate
dehydrogenase kinase, isozyme 1; AKT V-Akt murine thymoma viral
oncogene homolog 1; BCL-2 B cell CLL/lymphoma 2; BAD BCL2-
associated agonist of cell death; FOXO1 Forkhead box O1; FOXO3a
Forkhead box 3a; TSC1 tuberous sclerosis 1; TSC2 tuberous sclerosis 2;
mTOR mammalian target of rapamycin (serine/threonine kinase); AMPK
AMP-activated protein kinase; SRC SRC proto-oncogene, non-receptor
tyrosine kinase; RAC Ras-related C3 botulinum toxin substrate; JNK c-
Jun N-terminal kinase
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manner. These results indicate that H2AX phosphorylation is
regulated by p38 during serum starvation. In addition, serum
starvation increased the level of activated caspase-3, resulting
in apoptosis stimulation [41].
Nutrient starvation puts cells in alarm and induces them to
autophagy, a conserved self-eating process in which intracel-
lular membrane engulf a part of cytoplasmic organelles for
lysosomal degradation. Autophagy is a way by which cells
under starvation condition transfer nutrients from unnecessary
to essential processes [42]. The stimulation of autophagy by
starvation needs the activation of poly(ADP-ribose) polymer-
ase (PARP)-1, a nuclear enzyme switched on by DNA dam-
age. During starvation, ROS that could induce the activation
of PARP-1 are produced [43]. PARP-1 seems to be involved
in the hydrolysis of ADP ribose: its lack, in fact, does not
reduce ATP levels as much as when it is present [44]. As
result, the permanence of AMPK in an inactive state and the
consequent absence of the signal for mTOR inactivation were
detected, leading to impaired autophagy. An interesting in
vivo study suggested that PARP-1 regulates autophagy and
makes available a link between the PARP-1 function and over-
all cellular response to nutrient starvation. Then, starvation,
ROS production, and DNA damage cause PARP-1 activation
that is required for starvation-induced autophagy [43]. It is
well known that ROS-induced DNA damage consists of dif-
ferent lesions, including single-strand breaks (SSBs), double-
strand breaks (DSBs), and oxidized DNA nucleotides, the
most common of which is 8-oxo-7,8-dihydroguanine (8-
oxoG). The latter type of damage requires the intervention
of the base excision repair (BER) system, involving the repair
enzyme 8-oxoguanine DNA glycosylase (OGG1). It has been
observed that nutrient availability affects BER causing the
loss of OGG1 both in vitro and in vivo. In particular, the
induction of autophagy showed no consequence on OGG1
expression without starvation [45].
Dietary restriction and cancer
Tumor cells are exposed to numerous cellular stresses, such as
oncogene-induced genotoxic [46], oxidative [47], and meta-
bolic [48] stresses to which normal cells are not subjected.
That is why tumor cells are more dependent on stress by
supporting pathways for survival than normal cells.
Malignant cells undergo a series of genetic and epi-
genetic alterations that allow them to be both self-
sufficient for growth and non-sensitive to anti-growth
stimulation. Cancer cells express oncogenes that can
continue to relay the effect of growth factor, while
healthy cells are unable to grow in the absence of stim-
ulation. This independence could be explained by the
autocrine production of growth factors or by mutations
that make constitutively active intracellular signal
transduction proteins or membrane receptors. For exam-
ple, factors overproduced by cancer cells are platelet-
derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), and IGF-1 [49]. Probably, the
most important contribution regards alterations in genes
coding for components of the Ras/Raf/MAPK and
PTEN/PI3K/AKT pathways. In fact, mutated Ras alleles
can render the cell proliferation independent from extra-
cellular signals found in approximately a quarter of all
cancers [50] and, in particular, in half of colon cancers
[51].
In vitro serum starvation and in vivo short-term star-
vation reduce the levels of growth factors in normal
cells [52, 53]. Furthermore, in the same cells, the de-
pletion of paracrine communication signal of growth
factors reduces the activity of proliferation signaling
pathways and also the basal cellular metabolism.
Consequently, cells enter in a proliferative/quiescent sta-
tus [3]. Unlike healthy cells, it has been suggested that
cancer cells cannot rapidly adapt to fasting and thus
STS determines a differential stress resistance. Malignant
cells, in fact, struggle to adapt to the loss of external growth
factors by regulating autonomous growth stimulation and
reprogramming their metabolism, thereby maintaining contin-
uous proliferation [49]. This fundamental difference between
healthy and unhealthy cells may explain why starvation con-
dition protects normal cells without interfering with the killing
of malignant cells [21, 54] (Fig. 2).
In vitro and in vivo studies demonstrated that fasting
alone can modulate cell proliferation and apoptosis in
different types of tumors by determining an increased
cytotoxicity when combined with chemotherapy, the
main treatment for tumor injuries. Several chemotherapy
drugs harm DNA and cause cell death in part by pro-
moting oxidative damage that involves not only tumor
cells but also normal tissues (especially with high-dose
chemotherapy) [55]. This increase in ROS may act syn-
ergically with fasting and chemotherapy [19]. It seems
that the different types of dietary restriction selectively
protect normal cells from chemotherapy toxicity, sensi-
tizing simultaneously tumors to therapy, and STS is
much more effective than calorie restriction or long-
term fasting [21].
STS is able to sensitize various cancer types to chemo-
therapeutic agents. Some authors, in fact, showed that
growth factors and glucose restriction slowed proliferation
and increased cell death in 3 different murine cancer cell
lines, while 24 h of fasting before and after drug treatment
sensitized 15 of 17 cancer cell lines. They also evaluated
the effect of fasting in a model of human metastatic can-
cer by applying five cycles of fasting for 48 h in immu-
nosuppressed nude mice xenografted subcutaneously with
human neuroblastoma cells and comparing the results with
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normally fed mice. After 34 days, fasting cycles and cy-
clophosphamide treatment reduced tumor size to less than
a half of the one achieved in the treatment with cyclo-
phosphamide or fasting alone [19].
STS followed by chemotherapy is not only safe and
feasible but also helps to attenuate the side effects re-
lated to chemotherapeutic drugs. Some studies have
shown that STS induces cardioprotective effects against
the injury caused by doxorubicin [56]. Moreover,
Raffaghello et al. [54] studied the effects of high-dose
etoposide, a chemotherapeutic drug with a non-specific
toxicity profile, in murine models undergone to fasting
for 48–60 h, before the administration of a high-dose
drug, and in a control group fed ad libitum. The latter
group, after the treatment, showed many of the signs
associated with the toxicity of etoposide, including the
reduced mobility and the ruffled and posture alterations,
while mice submitted to fasting showed no obvious
signs of stress or pain. The beneficial effect of fasting
was confirmed by comparing the mortality rate of mice
in the two groups (43 % of the animals in the control
group), and only one case in the fasting group died
from acute toxicity by etoposide. A second group of
mice was starved for 60 h and then treated with a dose
of etoposide four or five times higher than the maxi-
mum dose recommended for humans. While non-starved
mice died or showed toxicity, starved mice only lost the
40 % of their weight, which was regained after 1 week
of re-feeding.
There is also an evidence of the benefits of the STS
before chemotherapy in humans. Ten volunteers affected
by different types of tumors were starved for 48–140 h
before chemotherapy and 56 h after the treatment. All
patients showed decreased chemotherapy-induced side
effects [54]. A period of fasting after chemotherapy
treatment could be relevant, because the combination
of re-feeding and drug-induced DNA damage can in-
crease the growth of aberrant foci in the liver, colon,
and rectum. This can be explained by the hypothesis
that prolonged fasting induces cell death and atrophy
in the organs and thus cell proliferation stimulated by
re-feeding can lead to a DNA damage, if high levels of
toxins are present [57, 58].
Effects of dietary restrictions on the main tumors
During disease, the interactions between tumor and stroma
cells are modified, producing a microenvironment that favors
the primary tumor growth (remodeling, invasion, and angio-
genesis) and its spreading (metastasis). Tumor microenviron-
ment is heterogeneous and, in addition to the tumor cells,
includes macrophages, fibroblasts, adipocytes, and endotheli-
al cells that appear different from those of normal tissues [59].
Among these, adipocytes suffer the influence of dietary re-
strictions and physical exercise. This condition implies that
dietary restrictions could be an effective method to favorably
change the tumor microenvironment and its activities [60].
Adipocytes localized near the tumor mass are called
Bcancer-associated adipocytes^ and show a reduction of adi-
pose markers, such as HSL, APN, and resistin, and an in-
creased expression of inflammatory cytokines (e.g., IL-6 and
IL-1β) [61]. Adipocytes play an important role in cancer pro-
gression and may contribute to carcinogenesis and tumor in-
vasiveness, since they are a source of pro-inflammatory cyto-
kines, such as IL-6 and TNF-α, ROS, and matrix
metalloproteases [62–65]. Moreover, adipocytes are able to
secrete adipokines that increase angiogenesis, fibrosis, and
inflammation by recruiting macrophages and endothelial cells
inside the cancer microenvironment in a way mediated by NF-
KB [66]. Dietary restriction can modulate the function of the
tumor microenvironment by altering the size of adipocytes
[63] and, consequently, reducing adipokine secretion, such
as IL-6 [67]. Furthermore, dietary approaches are often asso-
ciated with an increased life-span in mammalian and a better
response to chemotherapy in various types of cancer. It is well
known, in fact, that the bioavailability of several anticancer
oral drugs changes because of food exposure. Chemotherapy
Chemotherapy
Tumor cells
Drug-induced
cytotoxic effects
Dietary
Restriction
Healthy cells
Fig. 2 Effects of dietary
restrictions on effectiveness of
chemotherapy in cancer cells
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drugs are not the only cytotoxic strategy used for the treatment
of cancer. Evidences suggest that caloric restriction might also
be associated with radiation therapy (RT). Champ et al. [68]
reported that CR can modulate pathways involved in resis-
tance to treatment (such as IGF-1) and make cancer cells more
sensible to cytotoxicity induced by radiotherapy.
The standard chemotherapy can enhance cellular metabo-
lism by creating a tumor microenvironment rich in glucose
and glutamine. Recently, as an alternative to standard treat-
ment, metabolic therapies aimed to target metabolic alter-
ations present in all tumor cells and which give a benefit to
normal cells have been developed. For example, among the
metabolic therapies that improved the prognosis of patients
with glioblastoma multiforme and brain cancer, there is the
calorie-restricted ketogenic diet (KD-R), which shows anti-
angiogenic, anti-inflammatory, and anti-apoptotic effects [69].
Belowwe discuss some data in the literature concerning the
effects of dietary restrictions on the main tumors.
Breast cancer
Breast cancer is the most common cancer and represents the
first cause of the cancer death in women worldwide [70]. A
case report has shown the effect of a fasting period on
Caucasian women affected by breast cancer. The first case
was that of a 51-year-old woman (stage IIA) who has received
adjuvant chemotherapy (docetaxel and cyclophosphamide)
and has been subjected to fasting 140 h before and 40 h after
treatment. During fasting-chemotherapy cycle, the patient
showed no side effects in contrast to when she has undergone
chemotherapy alone. Even the complete blood count (CBC)
appeared best if the treatment was preceded by a period of
fasting. Another case was that of a 53-year-old woman (stage
IIA, HER2+) who has been exposed to four chemotherapy
cycles (with docetaxel and cyclophosphamide) and fasting
for 64 h before and 24 h post chemotherapy. Negligible side
effects were observed, including only mild weakness and
short-term memory impairment. The third case was represent-
ed by a 48-year-old woman treated with four cycles of doxo-
rubicin and cyclophosphamide followed by paclitaxel and
trastuzumab. During treatment, the patient was subjected to
fasting for 60 h prior and 5 h post drug administration, show-
ing no side effects associated with these drugs. The last report-
ed case was that of a 78-year-old woman (HER2+) submitted
to mastectomy and to six cycles of chemotherapy with
carboplatin, docetaxel, and trastuzumab. The patient adopted
fasting periods of variable lengths during therapy and, despite
this, has not been reported severe side effects [71]. Therefore,
it becomes apparent that a short period of fasting in associa-
tion with chemotherapy treatment improved patient’s tolera-
bility, reducing side effects even if underlying molecular
mechanisms are unclear. Factors related to the DNA repair
systems or apoptosis may be involved [72]. One of these is
REV1, a DNA polymerase involved in DNA repair, whose
role is to control cell metabolic fate. In a recent work, REV1
was indicated as a binding partner of p53 and, consequently,
as a regulator of its activity. Under fasting conditions,
SUMO2/3 (small ubiquitin-like modifier) induces changes in
REV1 by increasing the apoptotic effects of p53 on breast
cancer cells. The regulation of REV1 could be used as a
non-toxic strategy to increase p53-mediated cell death and
thus to improve the effectiveness of treatment [73].
Ovarian cancer
Ovarian cancer is the third most common gynecological can-
cer worldwide [74]. In vitro studies suggested that serum star-
vation reduces cell proliferation by inducing G1 arrest in hu-
man ovarian cancer cells (SK-OV-3), through the suppression
of Skp2-dependent CDK2 activity and Skp2-independent
CDK4 activity. Skp2 is an ubiquitin ligase that positively reg-
ulates cell cycle by inducing degradation of p27, resulting in
CDK2-induced progression from G1 to S phase [75].
A clinical study reported the case of a 44-year-old
Caucasian woman affected by ovarian cancer who, after a
series of drug resistances, has been treated with antineoplastic
drugs in combination with a fasting period of 62 h prior and
24 h after treatment. STS has been shown to improve the CBC
[71].
Colorectal cancer
Colorectal cancer (CRC) is the third most common can-
cer in men and the second in women worldwide [74].
Among the initial modifications causing the CRC onset,
there is the suppression of the serotonergic system that
seems to be related to a high-fat diet [76]. Moreover,
this type of diet enhances the formation of preneoplastic
lesions and consequently promotes CRC tumorigenesis
[77]. However, it has been shown that, during the ad-
vanced stages, the disease can induce a reduction of
serum total cholesterol levels [78]. Kaska et al. [79]
had evaluated the effects of a preoperative fasting peri-
od in CRC patients, observing no clinical benefit.
Conversely, intake of nutrients seems to be a protective
factor against surgical trauma. However, results about
the beneficial effects of dietary restrictions are conflict-
ing. Indeed, some authors reported that nutritional defi-
ciencies promote tumorigenesis because the lack of cer-
tain nutrients increases chemically induced carcinogene-
sis in preclinical models [80]. Furthermore, another
study evaluated the combined influence of a carcinogen
(1,2-dimethylhydrazine or DMH) and food deprivation
regimen in murine models. Food deprivation has been
shown to induce an increase of the lipid peroxidation
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processes in liver and colon tissues, suppressing the
serotonergic system in the colon [81].
Lung cancer
Lung cancer represents the most common cause of cancer
death worldwide [82]. The therapy of choice for patients with
locally advanced or metastatic non-small cell lung cancer
(with or without epidermal growth factor receptor (EGFR)
mutation) involves the use of erlotinib (an EGFR tyrosine
kinase inhibitor). Currently, its recommended dose is
150 mg daily, either 1 h before or 2 h after a meal. Katsuya
and colleagues [83] observed that these two types of fasting
determine a different drug absorption, resulting in increased
therapeutic effectiveness when drug administration occurs 2 h
after meal. Also, the authors found no major differences in
terms of toxicity or bioavailability between the two conditions
[83]. An interesting clinic case is represented by a 61-year-old
Caucasian woman with poorly differentiated non-small cell
lung cancer. During chemotherapy cycles, the patient experi-
enced numerous side effects that have been attenuated after
the implementation of fasting 48 h before and 24 h after che-
motherapy [71].
Prostate cancer
Prostate cancer is the second most common cancer in
men and the fifth leading cause of cancer death [74]. A
high-fat diet and a sedentary lifestyle can be considered
risk factors for the onset of prostate cancer by changing
the amount of hormones and growth factors in the se-
rum. An interesting study has recruited men with pros-
tate cancer randomly divided into two groups: one
group fed with a low-fat diet and the other without
restrictions. After 4 weeks, the serum was collected
from the patients and cultured with LNCaP prostate
cancer cells. The serum of both groups was not differ-
ent in terms of serum prostate-specific antigen (PSA),
sex hormones, insulin, IGF-1 and IGF-2, and insulin-
like growth factor-binding proteins, but serum triglycer-
ide and linoleic acid (omega-6) levels were decreased in
the low-fat diet group (in which omega-3 levels were
increased). It was observed that LNCaP cells in contact
with the serum of patients with low-fat diet grew very
slowly. Thus, a reduction in serum fatty acid levels may
induce a decrease in human LNCaP cell growth [84]. A
case report described the effect of a fasting period on
the response to an antineoplastic treatment in two
Caucasian men affected by prostate cancer. The first
case was that of a 74-year-old man with stage II pros-
tate adenocarcinoma and submitted to prostatectomy.
After therapy failure and severe side effects, the patient
was submitted to 60 h of fasting prior and 24 h post
chemotherapy. As result, a reduction of side effects and
PSA levels was observed compared to previous cycles
without STS. Similar results were obtained in a 66-year-
old man with prostate adenocarcinoma subjected to
fasting for 60–66 h prior and 8–24 h after chemothera-
py [71].
The beneficial effect of STS may be also observed
when the natural compound Guttiferone F (a prenylated
benzophenone derivative) is used. Guttiferone has been
shown to inhibit cell proliferation in prostate cancer cell
lines (LNCaP and PC3) submitted to serum starvation.
In this case, the compound leads to DNA fragmentation;
causes the entry of cells in the G1 phase; stimulates
mitochondria-dependent apoptosis, by regulating the
Bcl-2 family proteins; attenuates the androgen receptor
expression and ERK1/2 phosphorylation; but activates
JNK and calcium ion flow. The authors hypothesized
that the combination of dietary approaches and
Guttiferone F could increase the antitumor effect with-
out causing cytotoxicity in vivo [85].
In vivo studies investigated the effects of intermittent cal-
orie restriction (ICR) on mice xenografted with prostate can-
cer cells or transgenic adenocarcinoma mouse prostate
(TRAMP) models. Bonorden et al. [86] observed that ICR
(with a CR of 50 % lower than the classic feed) delays the
onset of cancer in TRAMPmice. If future studies will confirm
this data, STS could become an interesting strategy for pros-
tate cancer treatment.
Conclusions
Since dietary approaches represent an easy tool in delaying
aging, healing from damages, and preventing the onset of age-
related diseases, they may become efficient allies for
cooperating in the treatment of tumors, even though STS
seems to be more tolerated by sick patients. It is essential to
understand each change or hidden feature induced by the pro-
cesses described above to reap the benefits related to fasting.
The currently available data have associated the various
dietary approaches to numerous biological processes (from
cellular proliferation and vitality to inflammatory response)
and to the response to the chemotherapy. Recent studies have
reported that dietary restriction induces molecular changes in
genes, including IGF-1 and its receptor, as well as down-
stream effectors. The modification regards also inflammatory
cytokines and chemokines, such as IL-1β and TNF-α, and
elements associated to apoptosis (Bax/Bcl-x). However, addi-
tional insights are needed. Moreover, it might be interesting to
get more results in humans in order to ascertain the effect of
fasting and create standard protocols that are able to correlate
dietary approaches with chemotherapeutic treatments.
Tumor Biol.
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